Placebo News and Research

RSS

Study offers new insights into diagnosis and treatment of social dysfunctions

What if there were a pill that made you more compassionate and more likely to give spare change to someone less fortunate? UC Berkeley scientists have taken a big step in that direction.

20 Mar 2015

Targeted drug doubles progression free survival in Hodgkin lymphoma

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months).

19 Mar 2015

Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure. The condition, which affects nearly 6 million Americans and 23 million people worldwide, is marked by progressive weakening and stiffening of the heart muscle and the organ's gradual loss of blood-pumping ability.

19 Mar 2015

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases.

19 Mar 2015

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office.

19 Mar 2015

New study gives glimmer of hope for personalizing treatment for adrenal cancer

A new international study gives a glimmer of hope for personalizing treatment for one of the most rare and aggressive forms of cancer.

18 Mar 2015

Study investigates effects of antidepressant treatment in pain catastrophizing patients

A select population of patients having surgery experience what is called pain catastrophizing - an irrational thought process that leads a patient to perceive pain as worse than it actually is. Antidepressant medications reduce negative mood and might change this way of thinking, but according to a study published in the April edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, that may not be the case, at least for acute pain.

18 Mar 2015

New drug fails to prevent irreversible injury to the heart after angioplasty

Patients who received the new drug Bendavia before undergoing angioplasty or receiving a stent to clear blocked arteries after a heart attack showed no significant reduction in scarring as compared to patients given a placebo, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

18 Mar 2015

Sugar-lowering medications prescribed to diabetic patients may increase heart failure risk

A comprehensive study examining clinical trials of more than 95,000 patients has found that glucose or sugar-lowering medications prescribed to patients with diabetes may pose an increased risk for the development of heart failure in these patients.

17 Mar 2015

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04.

16 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

Common herpes drug Valacyclovir decreases HIV-1 levels

Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes.

16 Mar 2015

Mayo Clinic researchers find that energy drinks may increase risk of cardiac events

Healthy young adults who don't consume caffeine regularly experienced greater rise in resting blood pressure after consumption of a commercially available energy drink — compared to a placebo drink — thus raising the concern that energy drinks may increase the risk of cardiac events, Mayo Clinic researchers found.

16 Mar 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Mar 2015

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2014 and provided a corporate update.

13 Mar 2015

Study suggests distinct role of brain regions in dental pain relief

Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Michael L. Meier, Center for Dental Medicine, University of Zürich, Switzerland, will present a study titled "Distinct Brain Mechanisms Related to Dental Pain Relief."

13 Mar 2015

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families.

12 Mar 2015

Placebo News and Research

Study offers new insights into diagnosis and treatment of social dysfunctions

Targeted drug doubles progression free survival in Hodgkin lymphoma

Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

New study gives glimmer of hope for personalizing treatment for adrenal cancer

Study investigates effects of antidepressant treatment in pain catastrophizing patients

New drug fails to prevent irreversible injury to the heart after angioplasty

Sugar-lowering medications prescribed to diabetic patients may increase heart failure risk

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

Egalet announces net revenues of $1.9 million for 2014

Common herpes drug Valacyclovir decreases HIV-1 levels

Mayo Clinic researchers find that energy drinks may increase risk of cardiac events

Creatine monohydrate disappoints in Parkinson’s disease

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

Study suggests distinct role of brain regions in dental pain relief

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

Washington University researchers develop way to apply light-based therapy to reach deep tumors

Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News